New hope for PTSD: experimental drug trial targets service members and veterans

NCT ID NCT06816433

Terminated Symptom relief Sponsor: Global Coalition for Adaptive Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called SLS-002 to see if it can safely reduce PTSD symptoms in active-duty service members, veterans, and civilians. About 200 participants will receive either the drug or a placebo twice a week for 8 weeks, then once a week for 4 more weeks. The main goal is to measure changes in PTSD severity and monitor for any side effects or suicidal thoughts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-TRAUMATIC STRESS DISORDER

Contacts and locations

Locations

Advanced Discovery Research

Atlanta, Georgia, 30318, United States
Alexander T. Augusta Military Medical Center (ATAMMC):

Fort Belvoir, Virginia, 22060-5285, United States
Cincinnati Veteran's Affairs Medical Center

Fort Thomas, Kentucky, 41075, United States
Homestead Associates in Research, Inc.

Miami, Florida, 33032, United States
Madigan Army Medical Center

Joint Base Lewis McChord, Washington, 98433, United States
Tripler Army Medical Center (TAMC)

Tripler AMC, Hawaii, 96859, United States
Upstate Clinical Research Associates, LLC

Williamsville, New York, 14221, United States
Walter Reed National Military Medical Center (WRNMC)

Bethesda, Maryland, 20889-5632, United States
Wilford Hall Ambulatory Surgical Center (WHASC)

San Antonio, Texas, 78236, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.